Generic Name and Formulations:
Loteprednol etabonate 0.5% + tobramycin 0.3%, oph susp; contains benzalkonium chloride.
Bausch & Lomb Inc.
Indications for ZYLET:
Ocular inflammation associated with infection or risk thereof.
Instill 1–2 drops into the conjunctival sac of affected eye(s) every 4–6 hours; may increase to every 1–2 hours in first 24–48 hours; reduce dose as symptoms improve; max 20mL for first ℞. Reevaluate if no improvement after 2 days.
Ocular fungal, viral, or mycobacterial infections.
Corneal or scleral thinning. Glaucoma. Monitor IOP and for secondary infections and for cataracts in prolonged use (>10 days). Monitor blood levels in combined aminoglycoside therapy. Avoid abrupt cessation. Soft contact lenses (remove during therapy). Pregnancy (Cat.C). Nursing mothers.
Steroid + aminoglycoside.
Secondary ocular infections, injection, superficial punctate keratitis, increased IOP, ocular discomfort (eg, burning, stinging, itching, discharge) visual/lacrimation/eyelid disorder, photophobia, corneal deposits, headache. May mask or exacerbate ocular infections. May delay wound healing and increase bleb formation after cataract surgery. In prolonged use: increased IOP, optic nerve damage, cataract formation, corneal perforation.
Susp—2.5mL, 5mL, 10mL
Neurology Advisor Articles
- Excess Abdominal Obesity Linked to Severe Disability in Multiple Sclerosis
- Change in Dietary Patterns Over 5 Years in Early Multiple Sclerosis
- High-Dose Biotin May Be an Effective Treatment for Progressive MS
- Biobank Data Suggest Vitamin D Reduces Risk for Multiple Sclerosis
- Poor Functional Outcomes Tied to Depressive Symptoms in Multiple Sclerosis
- Managing Status Epilepticus in Palliative Care: Accounting for Patient and Family Experience
- Oxygen Desaturation Index Predicts AFib Risk in Ischemic Stroke
- Opioid Use Down With 'Enhanced Recovery After Surgery' Program
- Popular Heroin Inhalation Method Tied to Leukoencephalopathy
- Erenumab Superior to Placebo for Reducing Migraine Disability, Improving HRQoL